NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE Drug Patent Profile

When do Naphazoline Hydrochloride And Pheniramine Maleate patents expire, and what generic alternatives are available?

Naphazoline Hydrochloride And Pheniramine Maleate is a drug marketed by Altaire Pharms Inc and Rising and is included in two NDAs.

The generic ingredient in NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE is naphazoline hydrochloride; pheniramine maleate. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the naphazoline hydrochloride; pheniramine maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naphazoline Hydrochloride And Pheniramine Maleate

A generic version of NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE was approved as naphazoline hydrochloride; pheniramine maleate by ALTAIRE PHARMS INC on September 27^th, 2010.

Summary for NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	9
DailyMed Link:	NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE at DailyMed

Recent Clinical Trials for NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
EMS	Phase 3

See all NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE clinical trials

US Patents and Regulatory Information for NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Altaire Pharms Inc	NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE	naphazoline hydrochloride; pheniramine maleate	SOLUTION/DROPS;OPHTHALMIC	078208-001	Sep 27, 2010		OTC	No	No
Rising	NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE	naphazoline hydrochloride; pheniramine maleate	SOLUTION/DROPS;OPHTHALMIC	202795-001	Jan 24, 2013		OTC	No	No

Market Dynamics and Financial Trajectory of Naphazoline Hydrochloride and Pheniramine Maleate

Last updated: February 16, 2026

Overview

Naphazoline hydrochloride combined with Pheniramine maleate is an ophthalmic and nasal decongestant medication. The formulation targets allergic conjunctivitis, rhinoconjunctivitis, and related allergic conditions. It offers symptomatic relief by constricting blood vessels and reducing inflammation. The product's market presence is predominantly in over-the-counter (OTC) herbal and pharmaceutical segments across North America, Europe, and Asia.

Market Size and Growth

The global ophthalmic decongestants and antihistamines market was valued at approximately USD 1.7 billion in 2022. It projected a compound annual growth rate (CAGR) of around 4% between 2023 and 2028. The OTC segment constitutes roughly 65% of this market, emphasizing consumer accessibility.

Market Drivers

• Rising prevalence of allergic conjunctivitis and rhinitis globally.
• Growing aging population leading to increased ocular and nasal allergies.
• OTC availability facilitating ease of access and self-medication.
• Expansion in emerging markets with increased healthcare spending.

Market Challenges

• Limited product differentiation among OTC formulations.
• Competition from antihistamines and corticosteroids.
• Regulatory restrictions in various countries affecting OTC approvals.
• Concerns over systemic absorption and side effects influencing physician prescribing.

Competitive Landscape

Key players include Johnson & Johnson, Bausch + Lomb, and generic manufacturers across Asia and Europe. These companies focus on branding, formulation improvements, and packaging innovations to capture consumer loyalty.

Financial Trajectory

Current revenue contributions for products containing Naphazoline Hydrochloride and Pheniramine Maleate are modest, estimated at USD 150-200 million annually across global markets. This figure is driven by OTC sales and prescription segments, with North America contributing approximately 50% due to high prevalence and healthcare spending.

Projected growth points include:

• Market expansion in Asia-Pacific, expected to achieve a CAGR of 6-8% owing to increased health awareness.
• Introduction of combination formulations with longer shelf life and improved tolerability.
• Potential entry into new indications, such as ocular or nasal pain management, if clinical data support new uses.

Regulatory Environment

• In the U.S., OTC status is governed by the FDA, with monograph modifications influencing market access.
• Europe permits OTC sales under EMA guidelines but with specific limits regarding safety and labeling.
• Asian markets, such as India and Japan, have evolving regulations, with some formulations classified as prescription-only pending approval.

Intellectual Property and Patent Landscape

Patent expirations across major markets have increased generic competition. Original patent protection for formulations similar to Naphazoline Hydrochloride and Pheniramine Maleate has largely expired, with some regional patents in effect until 2025-2030, depending on jurisdiction.

Future Trends and Opportunities

• Development of sustained-release formulations for longer duration of action.
• Digital marketing and direct-to-consumer advertising to boost brand recognition.
• Increased pediatric and geriatric formulations to expand consumer base.
• Monitoring regulatory changes to maintain market access and compliance.

Key Takeaways

• The market for Naphazoline Hydrochloride and Pheniramine Maleate remains growing, driven by allergy prevalence and OTC availability.
• Competition from generics and other antihistamine products constrains margins.
• Emerging markets present significant growth opportunities, especially if regulatory pathways are navigable.
• Patent expirations will likely lead to increased generic penetration, affecting revenue streams.
• Innovation in formulations and strategic marketing are essential to sustain profitability moving forward.

FAQs

1. What are the main therapeutic uses of Naphazoline Hydrochloride and Pheniramine Maleate?
   They are primarily used to relieve allergy symptoms related to conjunctivitis and rhinitis.

2. How does patent expiration impact the market?
   It facilitates entry of generics, reducing prices and market share for original branded products.

3. What regulatory considerations affect OTC availability?
   Regulations differ globally; markets like the U.S. and Europe have strict OTC guidelines, while some Asian markets still require prescriptions.

4. Which regions offer the highest growth potential?
   Asia-Pacific offers the highest growth prospects due to increasing allergy prevalence and expanding healthcare infrastructure.

5. Are there emerging indications for these compounds?
   Current evidence supports their use mainly for allergy relief; exploratory research into other indications like ocular pain is ongoing but limited.

---

Sources:

1. MarketWatch, "Global Ophthalmic & Nasal Decongestants Market," 2022.
2. IQVIA, "OTC Drugs Market Trends," 2022.
3. European Medicines Agency, "Legislation on Medications," 2022.
4. U.S. Food and Drug Administration, "OTC Drug Review," 2023.
5. Industry Reports, "Pharmaceutical Patent Expirations," 2023.